Nelarabine

Generic Name
Nelarabine
Brand Names
Arranon, Atriance
Drug Type
Small Molecule
Chemical Formula
C11H15N5O5
CAS Number
121032-29-9
Unique Ingredient Identifier
60158CV180
Background

Nelarabine is an antineoplastic agent that is typically used to treat acute T-cell lymphoblastic leukemia, particularly T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), in both adult and pediatric patients whose disease has not responded to or has relapsed following at least two chemotherapy regimens. T-cell acute lympho...

Indication

ARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

Associated Conditions
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
Associated Therapies
-
Clinical Trials
Related News

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

First Posted Date
2024-04-30
Last Posted Date
2024-12-16
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
145
Registration Number
NCT06390319
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

First Posted Date
2024-01-18
Last Posted Date
2024-05-17
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT06210750

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

First Posted Date
2019-01-17
Last Posted Date
2024-08-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT03808610
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma

First Posted Date
2017-11-01
Last Posted Date
2023-07-21
Lead Sponsor
Emory University
Target Recruit Count
8
Registration Number
NCT03328104
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

🇺🇸

Cincinnati Children's Hospital, Cincinnati, Ohio, United States

and more 1 locations

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

First Posted Date
2017-04-18
Last Posted Date
2024-11-26
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
790
Registration Number
NCT03117751
Locations
🇺🇸

Children's Hospital of Michigan, Detroit, Michigan, United States

🇺🇸

St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States

🇦🇺

The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

and more 5 locations

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

First Posted Date
2017-01-13
Last Posted Date
2024-08-15
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
560
Registration Number
NCT03020030
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇨🇦

Hospital Sainte Justine, University of Montreal, Montreal, Quebec, Canada

and more 6 locations

Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

First Posted Date
2016-08-26
Last Posted Date
2024-10-10
Lead Sponsor
Goethe University
Target Recruit Count
1000
Registration Number
NCT02881086
Locations
🇩🇪

University Hospital of Frankfurt (Main), Frankfurt (Main), Germany

BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

First Posted Date
2016-05-05
Last Posted Date
2023-10-31
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
12
Registration Number
NCT02763384
Locations
🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)

Phase 2
Recruiting
Conditions
T-cell Adult Acute Lymphoblastic Leukemia
Interventions
Drug: nelarabine
First Posted Date
2015-12-02
Last Posted Date
2019-10-21
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
275
Registration Number
NCT02619630
Locations
🇫🇷

Hematology, Paris, France

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

First Posted Date
2015-08-10
Last Posted Date
2019-04-03
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
3
Registration Number
NCT02518750
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy